SubsidieMeestersGlycoRoads: A platform for the de novo design of glycans
GlycoRoads aims to develop an AI-driven platform for de novo glycan design using molecular dynamics simulations to create a comprehensive database, enhancing customization for therapeutic and material applications.
Projectdetails
Introduction
In the spirit of the various in silico de novo protein design products, GlycoRoads aims to introduce the world's first tool for de novo glycan design. Our cutting-edge screening platform will harness the power of molecular dynamics (MD) simulations to analyze hundreds of thousands of glycan structures, extracting crucial structural information to populate a comprehensive database (DB).
Database Development
This rich repository of data will serve as the foundation for an AI-driven user interface, designed to interrogate the DB and guide the de novo design of glycans that can adopt specific target conformations, greatly accelerating the exploration of their applications.
Importance of Glycans
The growing recognition of glycans' critical roles in biology and materials science underscores the transformative potential of our project. If successful, it will unlock unprecedented capabilities to customize glycans for targeted applications, opening new avenues in the design of next-generation therapeutics and materials.
Project Foundation
Within the ERC GlycoFold grant, our team has designed glycans with precise secondary structures. GlycoRoads builds on this groundwork to make the strategic design of glycans accessible to both academic and industrial researchers.
Objectives
This goal requires the completion of three critical objectives:
- Enhancing the current MD-based screening platform.
- Generating and systematically cataloging a vast array of data into a comprehensive and accessible DB.
- Developing an AI tool to leverage the DB to accelerate the design of glycans for diverse applications.
Anticipated Outcomes
The anticipated outcomes of our project—a detailed DB of glycan structures and a user-friendly interface for its interrogation—offer substantial commercialization prospects. Together, they pave the way for a groundbreaking shift in de novo glycan design across various fields.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-6-2025 |
| Einddatum | 30-11-2026 |
| Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EVpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Isotopically labelling of cell surface glycans to illuminate infectious processes at atomic resolutionGlyco13Cell aims to chemically remodel cell surface glycans using NMR probes to enhance understanding of glycan-lectin interactions for developing novel tools in infectious disease treatment. | ERC Starting... | € 1.500.000 | 2023 | Details |
Glycan foldamers: designing oligosaccharides to build three-dimensional architecturesThe project aims to develop synthetic carbohydrate foldamers that adopt defined structures and assemble into complex architectures, enhancing understanding and applications in chemistry and material science. | ERC Starting... | € 1.499.956 | 2023 | Details |
Imaging Single GlycoconjugatesGlycoX develops single molecule imaging methods to elucidate glycoconjugate structures, enhancing understanding for therapeutics and diagnostics in immune response and microbial infection. | ERC Starting... | € 2.000.000 | 2023 | Details |
Glycan Mimetics for Cell Glycocalyx Reconstitution: a polymer chemist’s approach to fight infectionGLYMCE aims to uncover how carbohydrates influence pathogen interactions to create innovative glycopolymer materials for infection prevention and treatment. | ERC Consolid... | € 1.994.024 | 2024 | Details |
Glyco-protein arrays for functional virus surveillanceThis project aims to assess the feasibility of glycan-protein arrays for early detection of pandemic influenza and coronavirus threats, enhancing public health surveillance. | ERC Proof of... | € 150.000 | 2024 | Details |
Isotopically labelling of cell surface glycans to illuminate infectious processes at atomic resolution
Glyco13Cell aims to chemically remodel cell surface glycans using NMR probes to enhance understanding of glycan-lectin interactions for developing novel tools in infectious disease treatment.
Glycan foldamers: designing oligosaccharides to build three-dimensional architectures
The project aims to develop synthetic carbohydrate foldamers that adopt defined structures and assemble into complex architectures, enhancing understanding and applications in chemistry and material science.
Imaging Single Glycoconjugates
GlycoX develops single molecule imaging methods to elucidate glycoconjugate structures, enhancing understanding for therapeutics and diagnostics in immune response and microbial infection.
Glycan Mimetics for Cell Glycocalyx Reconstitution: a polymer chemist’s approach to fight infection
GLYMCE aims to uncover how carbohydrates influence pathogen interactions to create innovative glycopolymer materials for infection prevention and treatment.
Glyco-protein arrays for functional virus surveillance
This project aims to assess the feasibility of glycan-protein arrays for early detection of pandemic influenza and coronavirus threats, enhancing public health surveillance.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Inhibitor-Mediated Programming of GlycoformsThe project aims to revolutionize glycan manipulation using Inhibitor-Mediated Programming of Glycoforms (IMProGlyco) to create precision-engineered therapeutic proteins and enhance cellular functions. | EIC Pathfinder | € 2.998.878 | 2025 | Details |
Precision control of glycosylation to open a new era of therapeutic antibodiesGlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments. | EIC Transition | € 2.499.540 | 2025 | Details |
Understanding the potential of modulating Host-Microbiome-Glycan interactions (“the triangle of sweetness”) to tackle non-communicable diseasesThe project aims to identify novel glycosyltransferases and HMOs, analyze their gut interactions, and validate an HMO for inflammation relief, enhancing glycobiology research and therapeutic applications. | EIC Pathfinder | € 3.920.718 | 2024 | Details |
Universal GPCR Activity Sensor for Next Generation Drug DiscoveryThis project aims to develop a novel single-assay technology platform for GPCR drug discovery, enhancing detection and classification of drug candidates to improve efficacy and reduce failures. | EIC Pathfinder | € 2.965.384 | 2023 | Details |
TraffikGene-Tx: Targeted Peptide Carriers for RNA DeliveryTraffikGene-Tx aims to develop safe, scalable peptide carriers for targeted RNA delivery, addressing genetic diseases and enhancing NAT therapies to improve patient outcomes and reduce healthcare costs. | EIC Transition | € 2.498.963 | 2023 | Details |
Inhibitor-Mediated Programming of Glycoforms
The project aims to revolutionize glycan manipulation using Inhibitor-Mediated Programming of Glycoforms (IMProGlyco) to create precision-engineered therapeutic proteins and enhance cellular functions.
Precision control of glycosylation to open a new era of therapeutic antibodies
GlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments.
Understanding the potential of modulating Host-Microbiome-Glycan interactions (“the triangle of sweetness”) to tackle non-communicable diseases
The project aims to identify novel glycosyltransferases and HMOs, analyze their gut interactions, and validate an HMO for inflammation relief, enhancing glycobiology research and therapeutic applications.
Universal GPCR Activity Sensor for Next Generation Drug Discovery
This project aims to develop a novel single-assay technology platform for GPCR drug discovery, enhancing detection and classification of drug candidates to improve efficacy and reduce failures.
TraffikGene-Tx: Targeted Peptide Carriers for RNA Delivery
TraffikGene-Tx aims to develop safe, scalable peptide carriers for targeted RNA delivery, addressing genetic diseases and enhancing NAT therapies to improve patient outcomes and reduce healthcare costs.